GLO Healthcare, an expanding healthcare platform formed by CapVest Partners LLP, has appointed David Herron as Calyx CEO. Herron brings a wealth of experience to Calyx, having spent more than thirty years building and growing life sciences businesses that provide advanced technology-enabled clinical scientific services to the global biopharma industry.
What does Herron bring to Calyx in the role?
Herron served as President and CEO of Bioclinica (now part of Clario). Under his leadership Bioclinica enjoyed a decade of revenue and profit growth, that delivered significant increase in enterprise value that led to the merger with ERT – creating a major player in the industry.
Commenting on his new role, David Herron said: “I am excited to join and lead Calyx, at a time that with new GLO Healthcare investors, there is an inspiring vision in place to accelerate the growth and development of the company. Building on the successes of Calyx to date, my focus will be on ensuring Calyx continues to deliver market-leading scientific knowledge and expertise, combined with excellent service and best in class technology-enabled services.”
What does the appointment mean for Calyx?
Commenting on the appointment, Renaud Dehareng, Executive Chairman of Calyx said: “We welcome David to the Calyx team. He is a leader of the highest caliber with a proven track record of putting momentum behind plans to bolster corporate growth and development.”
“For Calyx in particular, David’s expertise will enhance the depth, breadth, and quality of services to customers with an ultimate aim to deliver life-saving treatments to patients.”
Herron’s appointment is effective immediately and he succeeds Renaud Dehareng who has served as interim CEO since the acquisition of Calyx by GLO Healthcare in December 2022. Mr. Dehareng will now become Executive Chairman of Calyx. Kate Briant, Senior Partner at CapVest, will remain a member of the Calyx Board, and as chair of GLO Healthcare.
